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AbstRACt Reticular erythematous mucinosis (REM) is a rare form of pri-
mary cutaneous mucinosis, most often involving the midline of the upper 
chest or back in middle-aged women. REM bears clinical and histopatho-
logic resemblance to lupus erythematosus tumidus (LET), dermatomyosi-
tis, scleredema, and lichen myxedematosus. Early recognition and diagno-
sis of REM is particularly relevant to exclude the abovementioned diseases, 
as REM is more benign and has fewer systemic consequences. 
KEy WoRds: reticular erythematous mucinosis, lupus erythematous tu-
midus, scleredema, dermatomyositis, lichen myxedematosus, papular mu-
cinosis
IntRoduCtIon 
The cutaneous mucinoses are a diverse group of 
disorders in which elevated levels of mucin are found 
in the skin, predominantly in the dermis (1). The pri-
mary cutaneous mucinoses  are characterized by mu-
cin deposition as the major histological feature, and 
include scleromyxedema, scleredema, and lichen 
myxedematosus (papular mucinosis) among others 
(1). Secondary mucinoses are disorders in which mu-
cin deposition is an additional finding, and include lu-
pus erythematous, dermatomyositis and granuloma 
annulare (1). 
Reticular erythematous mucinosis (REM), first de-
scribed by Steigleder in 1974. is a rare form of primary 
cutaneous mucinosis, most often involving the mid-
line of the upper chest or back in middle-aged wom-
en (2,3). Within the heterogeneous group of disorders 
of cutaneous mucinosis, REM bears clinical and histo-
pathologic resemblance to lupus erythematosus tu-
midus (LET), dermatomyositis, scleredema, and pap-
ular mucinosis. However, recent evidence supports 
the recognition of REM as a distinct entity, based on 
its distinctive clinical and histologic features of this 
disorder. Therefore, early recognition and diagnosis 
of REM are particularly relevant, as it excludes lupus, 
scleredema, papular mucinosis or dermatomyositis. 
REM is more benign and has fewer systemic conse-
quences than the abovementioned diseases. 
EpIdEMIology of REM
REM is also known as plaque-like cutaneous mu-
cinosis or midline mucinosis (3,4). It usually is first 
evident as a non-scaly eruption of erythematous 
macules and papules in a reticulated pattern most 
commonly over the midline of the chest (3). In rare 
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cases, REM may also be evident on other sites such as 
the face, legs, arms, and abdomen (5).  Most often, pa-
tients are women in the third and fourth decades of 
life. They often have a relapsing and remitting course, 
with the disease limited to the skin (3,4).
Although the etiology is unknown, fibroblasts 
of patients with REM have an abnormal response to 
exogenous IL-1b (6). In addition, tubuloreticular in-
clusions have been detected in endothelial cells and 
pericytes within the skin lesions (6). The disease is ex-
acerbated by menses, contraceptives, and pregnancy, 
suggesting a possible hormonal basis. Solar exposure 
can flare it too, or in some cases improve the disease 
course. It may be associated with smoking (7), lupus 
erythematosus, diabetes mellitus, myxedema, hypo-
thyroidism, Hashimoto’s thyroiditis, thrombocytope-
nia, monoclonal gammopathy, HIV infection, breast 
cancer, and colon cancer (3,4). Immunologic distur-
bances and viral infections have also been postulated 
to be linked with the induction of REM syndrome  (7).
Fühler et al. (8) described monozygotic female 
twins who both presented with REM at almost the 
same time in the same location after UV exposure. 
Familial manifestations of REM syndrome are rare; an 
association with a distinct HLA constellation has not 
been proven. However, the almost simultaneous ap-
pearance of cutaneous lesions by light provocation at 
identical sites in these twin sisters suggests a genetic 
predisposition. 
Atci et al. delineated REM involving a mastectomy 
scar, the upper chest, and the midline of the back. 
This patient then underwent a mammary reconstruc-
tion involving an abdominal skin flap. The abdominal 
skin flap was lesion-free prior to the reconstruction; 
however, after the reconstruction, the abdominal 
skin flap demonstrated appearance of REM. As such, 
REM should be included in the differential diagnosis 
of persistent erythematous patches occurring on scar 
sites.
differential diagnosis for REM
Clinical diagnosis of REM is by exclusion, facili-
tated by clinical, histopathologic, and laboratory 
correlation to rule out lupus erythematous tumidus 
(LET), papular mucinosis (PM), dermatomyositis (DM) 
and scleredema (Table 1). Clinically, REM, LET, and DM 
can show erythematous plaque-like lesions with sig-
nificant lack of serologic abnormalities; however, the 
shape and distribution of lesions aid in distinction. 
REM’s principle lesion is more often a papule than a 
patch or plaque. Its reticulated pattern is distinct and 
most often involves the skin of chest, less commonly 
the upper back, with variable photosensitivity.
dermatomyositis (dM)
The primary skin lesions of DM are erythematous 
to violaceous papules and plaques, most often locat-
ed symmetrically on the extensor dorsal aspects of 
the metacarpophalangeal and interphalangeal joints 
(Gottron’s papules), with the second most common 
distribution being a heliotrope eruption of the up-
per eyelids. Both of these skin findings are pathog-
nomonic for DM (9). Less commonly, DM may pres-
ent with a maculopapular rash that may be related to 
photosensitivity, which can mimic the skin findings 
seen in REM patients. Other skin findings in DM in-
clude photo-distributed poikiloderma (neck, shawl), 
scalp dermatitis, nailfold telangiectasias, violaceous 
plaques over the knees and elbows, calcinosis cu-
tis (more in juvenile variant), and mechanic hands 
(ragged cuticles, hyperkeratosis, scaling, and fissur-
ing of distal fingers) (9). The muscular involvement 
is clinically characterized by symmetrical, proximal, 
progressive muscle weakness (9). It is important to 
note that muscular involvement is often seen in DM 
patients, and has not been associated with REM. 
A study by Edward et al. (10) found that the muci-
nous lesions may be caused by the presence of certain 
serum-derived factors. This work demonstrated that 
serum from patients with DM stimulates both sul-
phated glycosaminoglycan and hyaluronic acid syn-
thesis by fibroblasts from both control and involved 
skin. In contrast, the fibroblasts from patients with 
DM show similar levels of GAG synthesis as control 
fibroblasts in the presence of a control serum. These 
results suggest that these fibroblasts are not activat-
ed, nor contain a population of cells that overexpress 
GAGs. DM is frequently associated with the presence 
of an underlying malignancy (11). As DM is frequently 
associated with the presence of an underlying malig-
nancy, it is possible that the tumor may be releasing 
factors into the serum to promote the development 
of the characteristic mucinous lesions.
DM is primarily treated with steroids, though hy-
droxychloroquine, methotrexate, and azathioprine 
may also be used (9).  Maugers et al. (12) studied the 
long-term prognosis of patients with DM and found 
that survival rates were 82.6% at 1 year, 73.9% at 2.66 
years, 7% at 5 years and 55.4% at 9 years. The main 
prognostic factors were old age, cancer, pulmonary 
interstitial fibrosis and asthenia-anorexia.
lupus erythematosus tumidus (lEt)
LET is commonly first evident with erythema-
tous, urticarial-like single or multiple plaques with 
no surface changes such as follicular plugging.  They 
involve sun-exposed areas, especially the face, upper 
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table 1. Comparing REM, LET, DM, scleredema, and LM
REM LET DM Scleredema LM
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back, neck, extensor aspects of the arms, and shoul-
ders, and typically spare the knuckles, inner aspect of 
the arms, and axilla. They do not usually occur below 
the waist. LET can sometimes cause photosensitivity, 
and, as with REM, LET was also found to be highly as-
sociated with smoking (14). Although joint symptoms 
can occur temporarily, no signs of inflammatory joint 
disease is usually evident (13). A study by Kuhn et al. 
found that further systemic manifestations including 
renal, central nervous system, or lung involvement, 
had not manifested in any of the 40 study patients 
with LET for 15 years. Their study also showed that 
55% of the affected patients were male.  ANA was 
positive in 10% of the patients; anti–Ro/SSA and anti–
La/SSB antibodies were present in 5% of patients. Pa-
tients with LET are usually antimalarial responsive; 
the use of topical or intralesional corticosteroids as 
adjunctive therapies may be beneficial (15).
sClEREdEMA
Scleredema presents as diffuse, symmetric, non-
pitting skin induration caused by dermal glycosami-
noglycan deposits (16). It classically affects the upper 
back and posterior neck, causing skin tightness, and 
decreased range of motion. The affected areas are 
firm and woody plaques, sometimes slightly red or 
brown and often with a ‘peau d’orange’ (orange-skin) 
appearance. Scleredema occurs in individuals of all 
ages, with more than 50% of patients aged under 20 
years. Three types of scleredema have been described 
according to their association with underlying condi-
tions. Type 1 (the classic ‘Buschke’ type, 55% of cases) 
usually follows a febrile infection (especially strepto-
coccal or viral respiratory tract infection) and affects 
mainly children (16). Type 2 (25%) is associated with 
paraproteinemia including monoclonal gammopa-
thy, multiple myeloma and amyloidosis. Type 3 (20%) 
is associated with diabetes mellitus.  Other associated 
diseases include primary hyperparathyroidism,  rheu-
matoid arthritis, ankylosing spondylitis, Sjögren’s 
syndrome, dermatomyositis, Waldenstrom’s macro-
globulinemia, and IgA deficiency. Concomitant neo-
plasms have been reported, such as malignant insu-
linoma,  gall bladder carcinoma, carcinoid tumor and 
adrenocorticotropic hormone-producing pituitary 
tumour (17). In types 1 and 2 scleredema, women are 
affected almost twice as frequently as men. In con-
trast, in type 3 scleredema, the male- to-female ratio 
is considered to be 10:1 (16).
The treatment of scleredema remains a challenge, 
with therapeutic options including phototherapy, 
systemic corticosteroids, methotrexate, thalidomide, 
cyclosporine, plasmapheresis, and radiation (18). 
Kennemer et al. (17) found that IVIg was effective in 
treating scleredema with a longer duration of treat-
ment leading to a slower rate of relapse. However, no 
treatment has been shown to be consistently effec-
tive in large numbers of patients. Type 1 scleredema 
associated with a preceding infection is characterized 
by a good prognosis and even spontaneous resolu-
tion (17). Type 2 and Type 3 have poor prognosis, and 
may occasionally have chronic progressive courses 
and systemic complications. 
lIChEn MyxEdEMAtosus 
Lichen myxedematosus (LM) is characterized by 
fibroblast proliferation and mucin deposition in the 
dermis and is classified into two subtypes based 
upon severity. The milder, more localized type is 
called “papular mucinosis” and is also known as “li-
chen myxedematosus”. The other type is a severe, 
generalized more sclerotic and diffused form known 
as scleromyxedema. The localized form has a more 
favorable course compared to scleromyxoedema, 
which can involve other organs and is sometimes 
fatal (16). The disease usually affects adults between 
the ages of 30 and 80 years with no race or gender 
predominance.
Cutaneous findings include erythematous pap-
ules, in diameter from 1 mm to 4 mm (19). The papules 
are firm and waxy and are symmetrically arranged, 
primarily on the back of the hands and fingers, the 
extensor surface of the arms, the face, the upper tor-
so, and the legs. Scalp and mucosae are not affected. 
They may coalesce, resulting in widespread indura-
tion of the skin, eventually leading to leonine facies 
and microstomia. Erythema, edema and a brownish 
discoloration may be seen in the involved areas; pru-
ritus is also common (16). Eyebrow, axillary and pubic 
hair may be sparse in patients with scleromyxedema. 
The pathogenesis of scleromyxedema is unknown. 
The main hypothesis is that circulating cytokines such 
as IL-1, TNF-alpha and TGF-beta, which are known to 
stimulate glycosaminoglycan synthesis and fibroblast 
proliferation in the skin, are involved. The condition is 
usually associated with a monoclonal gammopathy. 
Scleromyxedema may also be involved with an un-
derlying neoplasm (20).
In a multicenter retrospective study of 30 patients 
with scleromyxedema, the most common extracuta-
neous manifestations were neurologic abnormalities 
(30%), rheumatologic abnormalities (25%) and cardi-
ac abnormalities (22% of patients) (21). The dermato-
neuro syndrome is a rare and potentially lethal acute 
neurologic complication characterized by fever, con-
fusion, dysarthria, lethargy, convulsions and coma 
(21,22).
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Scleromyxedema is a disease with an unpredict-
able but usually progressive and disabling course. 
The alkylating agent melphalan has been considered 
a first-line treatment, but has limited use due to its 
side effects (19). Other treatment options include 
cyclophosphamide, intralesional infiltration with hy-
aluronidase and triamcinolone, CO2 laser, methotrex-
ate, cyclosporine, radiotherapy, thalidomide, plasma-
pheresis, 2’-deoxyadenosine (2-CD), systemic cortico-
steroid, chloroquine, intravenous immunoglobulin, 
retinoids, chemotherapeutic agents, and PUVA (19).
CoMpARIng hIstology of REM, dM, 
lEt, sClEREdEMA, And lM
Histologically, subtle features can also help to 
identify REM as a distinct entity, while helping to 
differentiate its diagnosis from that of DM or LET. 
All three diseases show minimal epidermal change 
with dermal perivascular lymphocytic infiltrate and 
increased dermal mucin deposition.  Distinguishing 
features of DM include membrane attack complexes 
at the dermal-epidermal junction (DEJ) as well as in-
creased CD4 positivity when compared to LET (23). A 
recent study which analyzed features of LET and REM 
identified differences in the type and location of in-
flammatory infiltrate, mucin deposition, and immu-
noreactant deposition at the DEJ, helping to justify 
the distinction between the two and help guide diag-
nosis (24). In this retrospective and prospective study 
of 25 patients with REM, Cinotti and colleagues (24) 
observed a more prominent and deeper dermal in-
flammatory  infiltrate and deeper mucin deposition in 
LET when compared with REM.  A tropism for adnexa 
in LET was also noted. REM patients demonstrated 
both a more superficial inflammatory infiltrate and 
more superficial mucin deposition, as well as less fre-
quent immunoglobulin and complement deposition 
along the DEJ as compared to LET. In scleredema, the 
epidermis is also typically uninvolved, with the der-
mis being up to four times thicker than normal due 
to enlarged collagen bundles in deep reticular dermis 
with wide, clear, mucin-filled spaces between them. 
In LM the cutaneous biopsy shows an increase in 
mucin, with an increase in fibroblasts, and increased 
fibrosis. The extracutaneous LM histology sites may 
demonstrate mucin deposition in the subendothe-
lial space and in the interstitium of the kidney, lungs, 
pancreas, adrenal glands and nerves. Lymph node in-
volvement with infiltration by numerous fibroblasts 
surrounded by mucin and collagen deposits has also 
been observed.
Management of REM
Sun avoidance and protection are recommended 
as a first line therapy. Conventional antimalarial drugs 
like chloroquine, and hydroxychloroquine should be 
considered as a second option (7). Quinacrine may 
be used in patients that are allergic, or have certain 
eye diseases (25). Other treatments employed with 
variable results include topical tacrolimus, oral anti-
histamines, tetracycline, cyclosporine, UVB irradia-
tion, UVA1 irradiation (26), pulsed dye laser (27), and 
topical and systemic corticosteroids. It is important 
to note that REM is usually a self-limiting disease and 
may clear spontaneously, even after many years (1).
ConClusIon
In summary, REM should be considered in the dif-
ferential diagnosis of any non-scaly  erythematous 
maculopapular eruptions on the upper chest and up-
per back. Though it may present similarly to DM, LET, 
scleredema, and lichen myxedematosus, REM should 
be considered as a distinct entity. Entertaining the 
diagnosis of REM is particularly relevant for those pa-
tients who may have lupus, scleredema, or dermato-
myositis in their list of differential diagnoses, as REM 
is more benign and lacks systemic consequences. 
Furthermore, the prognosis for patients with REM 
is excellent, certainly favorable when compared to 
these other diseases. Clinicopathologic correlation is 
pivotal. 
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